Givosiran (Givlarri)

Givlaari (givosiran) is covered only for adults (≥18) for the FDA‑approved treatment of acute hepatic porphyria (AHP) when diagnosis is confirmed by clinical features plus elevated urinary ALA or PBG and the patient has had ≥1 porphyria attack in the prior 6 months requiring hospitalization, urgent care, or IV hemin. Coverage requires prescription by or consultation with a gastroenterologist/hepatologist/AHP specialist, submission of documentation (age, diagnostic labs, attack records), is limited to the FDA indication, and approvals are issued for up to 12 months (recommended dosing 2.5 mg/kg SC monthly).

"Givlaari is indicated for the treatment of adults with acute hepatic porphyria (AHP)."

Sign up to see full coverage criteria, indications, and limitations.